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Background:  Dolutegravir  (DTG)  is  an investigational  integrase  inhibitor  for treatment  of HIV  infection.
As  intravenous  drug  use  is  a common  risk  factor  for HIV,  this  study  evaluated  the  effect  of  DTG  on  the
pharmacokinetics  (PK)  of methadone.
Methods: This  was  an open-label,  2-period  study  in  adult,  opioid-dependent,  HIV-seronegative  subjects.
Subjects  received  their  current  individual  methadone  doses  once  daily  for 3  days  (Period  1)  followed
by  DTG  50  mg  twice  daily  (BID) for 5 days  while  continuing  their stable  methadone  therapy  (Period
2).  Serial  PK  samples  for R-  and  S-methadone  were  collected  after  each  Period.  Pharmacodynamic  (PD)
measures  and  safety  assessments  were  obtained  throughout  the study.  Non-compartmental  PK  analysis
was  performed,  and geometric  least-squares  mean  ratios  and  90%  conﬁdence  intervals  were  generated.
Results: Plasma  exposures  of total,  R-,  and  S-methadone  were  not  affected  by co-administration  of  DTG.
Mean  ratios  for AUC  were  0.98,  0.95,  and  1.01  for total,  R-,  and  S-methadone,  respectively,  alone  compared
with  in  combination  with  DTG. No  statistically  signiﬁcant  differences  were  noted  between  the  2  treatment
periods  in  methadone  PD  measures.  The  combination  of DTG  and methadone  was  well tolerated.  No
deaths,  serious  adverse  events,  or  grade  3/4  adverse  events  occurred.  No  clinically  signiﬁcant  changes  in
laboratory  values,  vital  signs,  or electrocardiograms  were  observed.
Conclusion: Co-administration  of  methadone  with  repeat  doses  of  DTG  50 mg  BID  had  no  effect  on total,
R-,  and  S-methadone  PK or  on  methadone-induced  PD  markers.  No  dose  adjustment  in methadone  is
required  when  given  in  combination  with  DTG.. Introduction
Intravenous drug use remains a signiﬁcant risk factor for HIV
nfection (Lansky et al., 2010). As such, methadone is commonly
iven for the treatment of opioid dependence in combination with
ntiretroviral drugs. However, co-administration is often compli-
ated by drug interactions between HIV treatments and methadone
Kharasch et al., 2009; Stocker et al., 2004; McCance-Katz et al.,
003). Antiretrovirals without signiﬁcant drug interactions may  be
dvantageous in this population.Dolutegravir  (DTG) is an integrase inhibitor with demonstrated
ctivity in HIV-infected patients (Rafﬁ et al., 2013; Eron et al., 2013).
TG is primarily metabolized via UDP-glucuronosyltransferase
∗ Corresponding author. Tel.: +1 919 483 2523; fax: +1 919 315 0151.
E-mail  address: stephen.c.piscitelli@gsk.com (S. Piscitelli).
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(UGT) 1A1 with a minor component of CYP3A4. It demonstrates
minimal or no direct inhibition of various CYP isozymes, UGTs,
and transporters and is not a metabolic inducer (Reese et al.,
2013). Methadone is metabolized by multiple isozymes, includ-
ing CYP2B6, CYP2D6, and CYP2C19, while CYP3A4 also plays a role
(Shiran et al., 2009).
Despite  the low potential for an interaction, there is a high like-
lihood for combination use, warranting an evaluation of DTG to
alter plasma concentrations of methadone. Also, since methadone
demonstrates no inhibition or induction effects on UGTs or CYPs,
this study only evaluated the effect of DTG on methadone and not
vice versa.
2. Methods
Open access under CC BY-NC-ND license.This was  an open-label, study in adult subjects who were identiﬁed at local
methadone  clinics and referred to the clinical study site. Subjects were required to
be on a stable dose of methadone at least 14 days prior to the pre-screening visit and
had to remain on the current dose for the duration of the study. Written informed
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onsent was  obtained from all subjects, and the study was  approved by IRB Services,
ntario,  Canada (ClinicalTrials.gov registry number NCT01467518).
Subjects had a pre-screening visit within 30 days prior to the ﬁrst dose of the
tudy  drug, 2 treatment periods, and a follow-up visit 7 to 14 days after the last dose.
ubjects received their individual doses of methadone once daily for 3 days (Period
) followed by DTG 50 mg  BID for 5 days to achieve steady-state while continuing
n  their stable methadone therapy (Period 2). Subjects were housed in the unit
uring treatment periods. DTG has been administered as 50 mg QD or 50 mg BID in
hase III trials. However, the 50 mg  twice daily regimen was selected in this study
o maximize the chance of ﬁnding an interaction.
Adult male and female subjects who were HIV and hepatitis C virus seronegative,
8–65  years of age, and enrolled in a methadone maintenance program for at least
2 weeks were eligible. The subject’s methadone dose had to have been unchanged
or  14 days prior to the pre-screening visit and had to be ≤200 mg  per day. Subjects
ere  judged to be healthy by physical exam, medical history, and laboratory test-
ng (complete blood count, hepatic function, electrolytes, creatinine, BUN). Subjects
ere permitted to use concomitant medications that were considered medically
ecessary  and were not expected to affect DTG pharmacokinetics (PK). Safety was
ssessed by adverse event (AE) reporting and by clinical and laboratory evaluations
hroughout  the study and at follow-up.
Serial PK samples for R- and S-methadone were collected on Period 1 Day 3 and
eriod 2 Day 5 after an 8-h fast at pre-dose, and then 1, 2, 3, 4, 6, 8, 12, 16, and 24 h
fter dosing. PK samples for DTG were collected pre-dose and then 1, 2, 3, 4, 6, 8,
nd 12 h after dosing. The Opioid Symptom Questionnaire and pupillometry were
mployed as pharmacodynamic (PD) measures. The summations were reported as
he overall opiate agonist and withdrawal scores. The questionnaire was adminis-
ered  on the PK days at the pre-dose and 2 h post-dose time points in both Periods 1
nd 2. A NeurOptics pupillometer (Irvine, CA, USA) was used to measure the mean
upil diameter for one eye. Data from a series of frames were used in the calculation,
nd  the ﬁnal display showed the weighted average and standard deviation (SD) of
he pupil size. Measurements were collected under mesopic lighting conditions. The
ight eye was  used for all assessments. If the right eye could not be scanned, the left
ye was  used. Assessments were done on PK days at time points 0, 1, 3, 6, 12, and
4  h.
.1.  Analytical methods
Plasma DTG was  extracted by protein precipitation with acetonitrile contain-
ng  the internal standard [15N2H7] DTG, injected onto a 2.1 mm × 50 mm,  3.5-m
Bridge  C18 column (Waters Associates, Milford, MA,  USA) and eluted with a
obile phase of 40% acetonitrile in aqueous 0.1% formic acid. Plasma R- and S-
ethadone, and their internal standard, [2H9](±) methadone, were extracted by
upported liquid extraction (ISOLUTE SLE+; Biotage, Uppsala, Sweden), injected onto
 2.0 mm × 50 mm,  5-m Chiral-AGP column (Chrom Tech, Apple Valley, MN,  USA),
nd eluted with 12% isopropyl alcohol in 10 mM ammonium acetate. The eluates
or  DTG, R-methadone, and S methadone were detected by a triple quadrupole
PI  4000 mass spectrometer (AB Sciex, Framingham, MA,  USA) using the posi-
ive ion mode and multiple reaction monitoring. Data acquisition and processing
ere  performed with Analyst 1.4.2 software (AB Sciex) using the validated calibra-
ion ranges of 0.020–2 g/mL for DTG, and 0.005–1 g/mL for R- and S-methadone.
otal  methadone concentrations were calculated by summation of the R- and S-
ethadone concentrations. The bias from the analysis of these study QC samples was
5.1 to 4.8% for DTG, −3.3 to 0.9% for R-methadone, and 2.0 to 4.9% for S-methadone.
he  precision for all analytes was ≤3.3%.
.2. Pharmacokinetic and statistical analyses
A sample size of 12 to obtain 10 evaluable subjects was  chosen based on an
xpected  withdrawal rate of approximately 20% and the within-subject variability
f  methadone. Non-compartmental PK analyses using WinNonlin, version 6.1 (Phar-
ight, Cary, NC, USA), were performed to determine parameters for methadone,
ethadone  isomers, and DTG, including area under the concentration–time
urve  from time zero until the end of the dosage interval (AUC(0−)), maximum
able 1
tatistical summary of methadone pharmacokinetic parameters.
Ratio of GLS means (90% CI)
AUC(0−) Cmax C0
Total methadone
B  vs A
0.98
(0.91,  1.06)
1.00
(0.94,  1.06)
0.97
(0.89,  1.05)
R-methadone
B  vs A
0.95
(0.89,  1.02)
0.97
(0.91,  1.03)
0.94
(0.87,  1.01)
S-methadone
B  vs A
1.01
(0.93,  1.09)
1.03
(0.97,  1.10)
1.00
(0.90,  1.10)
reatment A: Stable individual once-daily methadone dose. Treatment B: DTG 50 mg BID ×
TG,  dolutegravir; GLS, geometric least-squares; PK, pharmacokinetic.Hours
Fig. 1. Mean concentration–time proﬁles of R-, S-, and total methadone alone and
in combination with DTG. DTG, dolutegravir.
concentration (Cmax), and concentration at the end of the dosage interval (C). Log-
transformed PK parameters of R-methadone, S-methadone, and total methadone
were  calculated using mixed linear effects model (SAS 9.1; Cary, NC, USA) con-
sidering  treatment as a ﬁxed effect and subjects as a random effect. Geometric
least-squares  mean ratios for DTG plus methadone and methadone alone and
associated  90% conﬁdence intervals (CIs) were estimated. Change from baseline in
overall opiate agonist and withdrawal scores, change from baseline in minimum
pupil  diameter, and pupillometry area over the effect curve, calculated using a
mixed linear effects models (SAS 9.1), were used to test within-subject differences
across  study days (effect of DTG).
3. Results
3.1. Demographics
Twelve subjects were enrolled and 11 completed the study. One
subject was withdrawn due to an AE. The mean age was 34.5 years
(SD, 6.11). A similar number of males and females were enrolled (6
male, 5 female). All subjects were white. Methadone doses ranged
from 16 to 150 mg.3.2. Pharmacokinetics
Plasma PK proﬁles of R-, S-, and total methadone alone and
in combination with DTG are shown in Fig. 1. Exposures of total,
C Cmin CL/F R-/S-methadone
AUC  ratio
0.99
(0.91,  1.07)
0.98
(0.91,  1.06)
1.02
(0.95,  1.09)
NA
0.95
(0.89,  1.02)
0.95
(0.89,  1.01)
1.05
(0.98,  1.12)
0.94
(0.92,  0.97)
1.02
(0.93,  1.12)
1.01
(0.92,  1.12)
0.99
(0.92,  1.07)
NA
 5 days + stable individual methadone dose. BID, twice daily; CI, conﬁdence interval;
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-, and S-methadone were not affected by co-administration of
TG 50 mg  BID. Geometric mean ratios were approximately 1.0,
nd all 90% CIs were within 0.8 and 1.25 for AUC, Cmax, and C
Table 1). The ratio of R-/S-methadone when methadone was  given
ith DTG compared with methadone alone was 0.94, suggesting
hat co-administration with DTG did not affect the proportion of
ach isomer. Geometric mean (coefﬁcient of variation) PK param-
ters of DTG were 44.3 (37) g h/mL for AUC(0−), 4.88 (35) g/mL
or Cmax, and 2.63 (37) g/mL for C.
.3. Pharmacodynamics
.3.1. Opiate agonist and withdrawal scores. No statistically signif-
cant difference (P > 0.10) was noted between subjects receiving
ethadone alone and subjects receiving DTG + methadone for
hange from baseline in overall opiate agonist and withdrawal
cores. The change from baseline in overall opiate agonist score
as 4.52 for methadone alone and 4.48 for the combination, with a
ean difference (combination minus methadone alone) in change
rom baseline of −0.05 (SD, 31.0; 90% CI for the mean difference,
58.69 to 58.59). The change from baseline in overall withdrawal
core was -56.3 for methadone alone and −40.8 for the combina-
ion, with a mean difference (combination minus methadone alone)
n change from baseline of 15.6 (SD, 12.1; 90% CI for the mean
ifference, −6.77 to 37.9).
.3.2.  Pupillometry. No signiﬁcant difference in change from base-
ine in pupillometry scores was noted between subjects receiving
ethadone compared with DTG + methadone. The change from
aseline in minimum pupil diameter was −1.47 for methadone
lone and −1.48 for the combination (point estimate −0.01; 90%
I, −0.30 to 0.28). No signiﬁcant difference in pupillometry area
ver the effect curve was also noted between subjects receiving
ethadone compared with DTG + methadone. At all time points
valuated, 90% CIs around the point estimate of test minus refer-
nce (combination minus methadone alone) included the value of
ero.
.4. Safety
There were no serious or grade 3/4 AEs. The most com-
only reported drug-related AEs were headache (27%) and fatigue
18%). All drug-related AEs were reported in subjects receiv-
ng DTG + methadone. Two subjects experienced drug-related AEs
hat were moderate (grade 2) in intensity. One subject experi-
nced moderate dizziness. Another subject experienced moderate
eadache, hematuria, and panic attack and was withdrawn from
he study; the AE resolved after 1 day. The subject did not expe-
ience any pain with the hematuria and was referred for an
ltrasound and to a urologist. No treatment-related or clinically
igniﬁcant trends in hematology or clinical chemistry values were
bserved in the study. No clinically signiﬁcant abnormal electro-
ardiogram values or changes in vital signs were observed.
.  Discussion
Methadone is administered as a chiral mixture of R and S
somers in which the opioid effect is primarily mediated through R-
ethadone (Eap et al., 2002). The addition of DTG to individualized
table methadone therapy had no effect on total, R-, and S-
ethadone PK. Additionally, the AUC ratios of R- and S-methadonehowed no signiﬁcant differences between the 2 treatments, sug-
esting an absence of a stereo-speciﬁc effect of DTG. These results
ere consistent with previous studies, which showed slightly
ower R-methadone compared with S-methadone exposures (Caoendence 133 (2013) 781– 784 783
et al., 2008; Crauwels et al., 2010; Van Heeswijk et al., 2011). The
AUC difference between these 2 isomers was approximately 10%.
The results of this study are consistent with previous data show-
ing DTG does not affect other drugs that are metabolized by CYP3A,
such as midazolam and oral contraceptives (Song et al., 2013; Min
et al., 2011). These negative ﬁndings are important for clinicians to
guide dosing of DTG in subjects in methadone maintenance pro-
grams.
DTG PK parameters observed in this study were comparable to
other DTG PK studies in which DTG was  administered BID (Dooley
et al., 2013; Koteff et al., 2013). Given the limitations of a cross-
study comparison, there did not appear to be a signiﬁcant effect of
methadone on DTG PK. An additional limitation of the study was
the small sample size. However, the low to moderate variability of
methadone and cross-over design of the study support the ﬁndings.
PD measurements were incorporated in the event that DTG
signiﬁcantly altered the PK of methadone. Even in the presence
of PK differences, PD evaluations can determine whether differ-
ences in exposure translate to clinically signiﬁcant effects. Two
PD measurements were employed in this study, the Opioid Symp-
tom Questionnaire and pupillometry. Overall, co-administration of
repeat doses of DTG had no effect on the PD parameters. There
were no statistically signiﬁcant differences noted between sub-
jects receiving methadone alone and subjects receiving DTG plus
methadone for change from baseline in overall opiate agonist
and withdrawal scores. No signiﬁcant differences were also noted
between treatment periods in pupillometry scores.
No  differences were observed in either PK or PD measure-
ments, demonstrating the lack of interaction between DTG and
methadone. These data demonstrate that no dose adjustments in
methadone are required when DTG is co-administered.
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